Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A <i>Post-hoc</i> Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Authors
Stephen Weng (ORCID: https://orcid.org/0000-0002-5281-9590)
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Stephen Weng, Wei Gu, Danrong Yang, Cui Xiong et al.
Citations
2 citations
Journal
Allergy Asthma and Immunology Research
Topics
Asthma and respiratory diseases
Field-Weighted Citation Impact (FWCI)
2.33
article
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Stephen Weng, Wei Gu, Danrong Yang, Cui Xiong, Ruchong Chen, Peter Howarth, Qiong Zhou, Jie Cao, Wei Han, Jie Huang, Chuntao Liu, Nanshan Zhong, Peiwen Liang, Yuanrong Dai
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Allergy Asthma and Immunology ResearchVol. 17(4)
Institutions
Qingdao University (CN), Union Hospital (HK), Sichuan University (CN), Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN), Tianjin Medical University General Hospital (CN), West China Hospital of Sichuan University (CN), Shanghai Ninth People's Hospital (CN), First Affiliated Hospital of Guangzhou Medical University (CN), Qingdao Municipal Hospital (CN), MRC Biostatistics Unit (GB), GlaxoSmithKline (China) (CN), Shanghai Sixth People's Hospital (CN), Huazhong University of Science and Technology (CN), Nanjing Medical University (CN), Guangzhou Medical University (CN)